Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions worldwide. This complex liver disorder ranges from simple steatosis to more severe forms, including metabolic dysfunction-associated steatohepatitis (MASH), which may progress to fibrosis, cirrhosis, and even liver cancer.
Study reveals the role of transcription factors as therapeutic gateways in MAFLD
- Post author:admin
- Post published:March 11, 2025
- Post category:uncategorized